BioCentury | May 28, 2020
Management Tracks

Quick departure for Semerjian as Immunomedics CEO; plus Ziopharm, Kinnate, Applied Therapeutics, Relmada, AskBio and more

Less than two months after becoming president and CEO of Immunomedics Inc. (NASDAQ:IMMU), Harout Semerjian is stepping down because of “unfortunate significant logistical obstacles presented by the COVID-19 pandemic,” according to the cancer company. Executive...
BioCentury | May 19, 2020
Product Development

May 18 Quick Takes: ChemoCentryx’s Phase II miss; plus Teva, Zai-Novocure, Lava-J&J, Sanofi, Rhythm, ViiV

ChemoCentryx therapy fails Phase II study in rare renal disorder  ChemoCentryx Inc. (NASDAQ:CCXI) and partner Vifor Fresenius Medical Care Renal Pharma said CCX140 failed to meaningfully reduce proteinuria vs. control in a Phase II study...
BioCentury | Apr 4, 2020

Steady as venBio goes

A day after Arch and Flagship unveiled dueling billion dollar funds, venBio is staying the course with a more modest $394 million fund. What is new for the nine-year-old firm is a dramatic shift away...
BioCentury | Mar 21, 2020

Design debuts with $45M series A, portfolio against repeat expansions

Design Therapeutics emerged from stealth Friday with a $45 million series A and a portfolio of bifunctional small molecules to treat degenerative disorders caused by nucleotide repeat expansions, starting with Friedreich's ataxia. SR One led...
BioCentury | Mar 20, 2020
Product Development

Industry to boost supply of chloroquine, hydroxychloroquine despite limited data in COVID-19

Novartis and Teva join a growing list of pharmas with plans to ramp up supply of antimalarial drug hydroxychloroquine in the U.S. for COVID-19 despite sparse clinical data supporting the drug's efficacy in the indication....
BioCentury | Mar 19, 2020
Product Development

DARPA’s gambles might have created the best hopes for stopping COVID-19

A U.S. defense agency that specializes in turning science fantasies into realities jump-started technologies and nurtured companies that are now at the forefront of the response to the COVID-19 pandemic. The Defense Research Advanced Projects...
BioCentury | Mar 16, 2020
Product Development

Teva, Celltrion launch fourth U.S. Herceptin biosimilar at modest discount

Teva and Celltrion Monday launched Herzuma trastuzumab-pkrb, a biosimilar version of Genentech’s Herceptin trastuzumab, in the U.S. at a 10% discount to the original product. The launch price suggests that unlike generic drugs, the launch...
BioCentury | Feb 22, 2020
Product Development

FDA approves Lundbeck's Vyepti, the first CGRP inhibitor for migraine delivered IV

FDA's approval of Vyepti eptinezumab-jjmr from Lundbeck is the first for an IV-delivered CGRP inhibitor for migraine prevention, but the therapy will face competition from established subcutaneous drugs in its class. Already on the market...
BioCentury | Feb 21, 2020
Product Development

Feb. 20 Product Development Quick Takes: Priority Review puts BioMarin on track to score first hemophilia gene therapy approval in U.S.; plus Gilead-CDC, Genfit

BioMarin's hemophilia gene therapy gets Priority Review  BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) could become the first company to have a hemophilia gene therapy approved in the U.S. FDA accepted and granted Priority Review to a BLA...
BioCentury | Feb 15, 2020
Management Tracks

Immunomedics names Itri CMO; plus Hua, GenMark, AAM, Vividion, Sophia Genetics, Enterprise, Encoded, Palleon and more

Antibody-drug conjugate company Immunomedics Inc. (NASDAQ:IMMU) hired Loretta Itri as CMO. She was EVP of global health sciences and regulatory affairs at The Medicines Co. (NASDAQ:MDCO). Shanghai-based diabetes company Hua Medicine Ltd. (HKEX:2552) hired Fuxing...
Items per page:
1 - 10 of 2179